Cargando…
Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma
The aim of the present study was to compare the effectiveness of transarterial chemoembolization (TACE), TACE combined with Jie-du granules (JD), and TACE combined with sorafenib (SOR) for treating patients with unresectable hepatocellular carcinoma (HCC). For this purpose, we conducted a retrospect...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542181/ https://www.ncbi.nlm.nih.gov/pubmed/28423370 http://dx.doi.org/10.18632/oncotarget.16804 |
_version_ | 1783254936053612544 |
---|---|
author | Zhao, Hetong Zhai, Xiaofeng Chen, Zhe Wan, Xuying Chen, Lanyu Shen, Feng Ling, Changquan |
author_facet | Zhao, Hetong Zhai, Xiaofeng Chen, Zhe Wan, Xuying Chen, Lanyu Shen, Feng Ling, Changquan |
author_sort | Zhao, Hetong |
collection | PubMed |
description | The aim of the present study was to compare the effectiveness of transarterial chemoembolization (TACE), TACE combined with Jie-du granules (JD), and TACE combined with sorafenib (SOR) for treating patients with unresectable hepatocellular carcinoma (HCC). For this purpose, we conducted a retrospective analysis of data from 266 consecutive patients with unresectable HCC who underwent TACE treatment at the Shanghai Hospital and Eastern Hepatic Surgery Hospital between Jan 2009 and Dec 2010. We prospectively analyzed patient survival and progression times as well as independent predictors, within a follow-up period of 86 months. Patients were divided into TACE-JD (n = 75), TACE-SOR (n = 124) and TACE (n = 67) groups. Median overall survival (OS) times being: TACE-JD, 21.43 months; TACE-SOR, 23.23 months; TACE, 13.97 months (TACE-SOR vs TACE, P < 0.001; TACE-SOR vs TACE-JD, P = 0.852; TACE-JD vs TACE, P < 0.001). The median times to progression (TTP) were as follows: TACE-JD, 8.67 months; TACE-SOR, 5.37 months; TACE, 4.57 months (TACE-SOR vs TACE, P = 0.479; TACE-SOR vs TACE-JD, P < 0.001; TACE-JD vs TACE, P < 0.001). Independent predictors of OS were treatment allocation, Child-Pugh class large tumor, albumin and extrahepatic metastasis. These findings show that patients with unresectable HCC who were administered TACE-JD survived significantly longer compared with those administered TACE or TACE-SOR. |
format | Online Article Text |
id | pubmed-5542181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-55421812017-08-07 Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma Zhao, Hetong Zhai, Xiaofeng Chen, Zhe Wan, Xuying Chen, Lanyu Shen, Feng Ling, Changquan Oncotarget Research Paper The aim of the present study was to compare the effectiveness of transarterial chemoembolization (TACE), TACE combined with Jie-du granules (JD), and TACE combined with sorafenib (SOR) for treating patients with unresectable hepatocellular carcinoma (HCC). For this purpose, we conducted a retrospective analysis of data from 266 consecutive patients with unresectable HCC who underwent TACE treatment at the Shanghai Hospital and Eastern Hepatic Surgery Hospital between Jan 2009 and Dec 2010. We prospectively analyzed patient survival and progression times as well as independent predictors, within a follow-up period of 86 months. Patients were divided into TACE-JD (n = 75), TACE-SOR (n = 124) and TACE (n = 67) groups. Median overall survival (OS) times being: TACE-JD, 21.43 months; TACE-SOR, 23.23 months; TACE, 13.97 months (TACE-SOR vs TACE, P < 0.001; TACE-SOR vs TACE-JD, P = 0.852; TACE-JD vs TACE, P < 0.001). The median times to progression (TTP) were as follows: TACE-JD, 8.67 months; TACE-SOR, 5.37 months; TACE, 4.57 months (TACE-SOR vs TACE, P = 0.479; TACE-SOR vs TACE-JD, P < 0.001; TACE-JD vs TACE, P < 0.001). Independent predictors of OS were treatment allocation, Child-Pugh class large tumor, albumin and extrahepatic metastasis. These findings show that patients with unresectable HCC who were administered TACE-JD survived significantly longer compared with those administered TACE or TACE-SOR. Impact Journals LLC 2017-04-03 /pmc/articles/PMC5542181/ /pubmed/28423370 http://dx.doi.org/10.18632/oncotarget.16804 Text en Copyright: © 2017 Zhao et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Zhao, Hetong Zhai, Xiaofeng Chen, Zhe Wan, Xuying Chen, Lanyu Shen, Feng Ling, Changquan Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma |
title | Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma |
title_full | Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma |
title_fullStr | Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma |
title_full_unstemmed | Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma |
title_short | Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma |
title_sort | transarterial chemoembolization combined with jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542181/ https://www.ncbi.nlm.nih.gov/pubmed/28423370 http://dx.doi.org/10.18632/oncotarget.16804 |
work_keys_str_mv | AT zhaohetong transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma AT zhaixiaofeng transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma AT chenzhe transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma AT wanxuying transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma AT chenlanyu transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma AT shenfeng transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma AT lingchangquan transarterialchemoembolizationcombinedwithjiedugranulepreparationimprovesthesurvivaloutcomesofpatientswithunresectablehepatocellularcarcinoma |